2Huang H, Liu YX, Zhan ZL, et al. Different sites and prognoses of gastrointestinal stromal tumors of stomach: report of 187 cases. World J Surg ,2010,34 (7) : 1523-1533.
3Takiguchi S, Masuzawa T, Hirao T, et al. Pattern of surgical treatment for early gastric cancer in upper third of the stomach. Hepatogastroenterology ,2011,58 ( 110-111 ) : 1823-1827.
4NCCN. The NCCN soft tissue sarcoma clinical practice guidelines in oncology ( version 1. 2011 ) [ EB/OL ]. Fort Washington: NCCN, 2011 [2011-07-29]. http://www, nccn. org/professionals/physi- cian-gls/f-guidelines, asp.
5Joensuu H, Eriksson M, Hartmann J, et al. Twelve vs 36 months of adjuvant imatinib ( IM ) as treatment of operable GIST with a high risk of recurrence : final results of a randomized trial ( SSGX- VIII/AIO). J Clin Oneol 2011,29( 15 Suppl):LBA1.
6Joensuu H. Risk stratification of patients diagnosed with gastroin- testinal stromal tumors. Hum Pathol,2008,39(10) :1411-1419.
7Kukar M, Kapil A, Papenfuss W, et al. Gastrointestinal stromaltumors(GISTs) at uncommon locations: A lange population basedanalysis [j]. J Surg Oncol, 2015, [Epub ahead of print ].
8Huang H, Liu YX, Zhan ZL, et al. Different sites and prognosesof gastrointestinal stromal tumors of stomach: report of 187 oases[J]. World J Surg, 2010,34(7):1523-1533.
9Joensuu H,Eriksson M, Hartmann J, et al. Twelev vs 36 monthsof adjuvant imatinib(IM) as treatment of operable GIST with ahigh risk of recurrence: final results of a randomized trial(SSGX—VIII/AI0)[j]. J Clin Oncol, 2011,29(15 suppl):LBAI.
10Joensuu H. Risk stratification of patients diagnosed with gastro-intestinal stromal tumors [J]. Hum pathol, 2008,39(10):1411-1419.
